BTIG Research Cuts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $134.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective trimmed by BTIG Research from $138.00 to $134.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also commented on KYMR. Wells Fargo & Company lifted their price target on Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Guggenheim started coverage on Kymera Therapeutics in a research note on Monday, November 3rd. They issued a “buy” rating and a $90.00 price objective for the company. Citigroup lifted their target price on Kymera Therapeutics from $80.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. B. Riley Financial increased their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, Jefferies Financial Group raised their price target on Kymera Therapeutics from $73.00 to $122.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $117.60.

Kymera Therapeutics Stock Performance

KYMR stock opened at $91.35 on Thursday. The firm has a fifty day moving average price of $78.52 and a 200 day moving average price of $65.44. Kymera Therapeutics has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The firm has a market cap of $6.57 billion, a PE ratio of -24.82 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 34.12%. The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter last year, the business earned ($0.88) EPS. Kymera Therapeutics’s revenue for the quarter was down 60.8% compared to the same quarter last year. On average, equities analysts predict that Kymera Therapeutics will post -2.79 EPS for the current year.

Insider Activity

In other news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares of the company’s stock, valued at approximately $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jared Gollob sold 49,307 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the sale, the insider directly owned 109,992 shares of the company’s stock, valued at $9,752,990.64. This represents a 30.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 450,895 shares of company stock valued at $40,486,151. Insiders own 16.01% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP raised its position in Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC increased its stake in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares during the period. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares in the last quarter. Finally, BVF Inc. IL lifted its stake in Kymera Therapeutics by 6.6% in the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after acquiring an additional 340,909 shares during the period.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera announced its degrader candidate KT‑579 has entered first‑in‑human (Phase 1) testing — an important de‑risking milestone that validates the Pegasus platform and expands the company’s clinical-stage pipeline. Article Title
• Positive Sentiment: Management reported a large cash infusion (~$1.6B) that materially extends the company’s cash runway into 2029 and supports planned development (including KT‑621), reducing near‑term dilution risk. This funding, combined with ongoing program progress, is a key positive for valuation and execution. Article Title
• Positive Sentiment: Analyst sentiment remains constructive: Piper Sandler raised its price target to $140 and the consensus analyst posture is still broadly a “Buy,” supporting potential upside from upgrades and model revisions. Article Title
• Neutral Sentiment: Kymera reiterated plans to read out KT‑621 Phase IIb data in 2027 — a clear catalyst for 2027 but distant; this keeps the company in a development‑stage timeline where interim updates will matter to sentiment. Article Title
• Negative Sentiment: Q4 results missed expectations — EPS of ($0.97) vs. consensus ($0.77) and revenue of $2.87M vs. $14.8M (down ~60% y/y). The larger loss and revenue shortfall triggered near‑term selling and raises questions on near‑term commercial/collaboration cadence. Article Title
• Negative Sentiment: Insider selling: CEO Nello Mainolfi sold 30,000 shares (~$2.7M). While not uncommon for executives to monetize, multiple recent sales may weigh on investor sentiment in the short term. Article Title

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.